Gannex Galmed Enter Into Research Agreement For Nash Treatment

Gannex Galmed Enter Into Research Agreement For Nash Treatment

By, Admin 11 September 2020

China-Based Gannex Pharma Co. Ltd., A Wholly-Owned Company Of Ascletis Pharma Inc. And Galmed Pharmaceuticals Ltd. In Israel Have Recently Announced That They Have Entered Into A Research Agreement Aiming At Combination Therapy Of Asc41 (Thr-Beta Agonist) And Aramchol (Scd 1 Inhibitor) For The Treatment Of Non-Alcoholic Steatohepatitis (Nash).Asc41 Is An Oral Thyroid Hormone Receptor Beta (Thr-Beta) Agonist Which Recently Received Ind Approval From China'S National Medical Products Administration (Nmpa) To Conduct Clinical Trials For Nash Indication. Topline Data Of Phase I Safety, Pk And Preliminary Efficacy (Ldl-C) In Healthy Volunteers With Ldl-C ≫ 110 Mg/Dl Is Expected To Be Available By The End Of 2020.Asc41'S Active Moiety Selectively Activates Thr-Beta Resulting In The Improvement Of Steatosis/Lipotoxicity, Inflammation, Ballooning, Fibrosis In Both Direct And Indirect Manner. In Two Nash Animal Models, Asc41 Demonstrated The Same Improvement In Liver Steatosis, Inflammation And Fibrosis At 1/10 Dose Of Resmetirom (Mgl-3196), Another Thr-Beta Agonist Currently In Phase Iii Clinical Trial.In Hepatocytes, The Reduction Of Scd 1 Results In Elevation Of Ampk, Fa Oxidation And Glutathione Ratio. In Hsc'S Inhibition Of Scd 1 Results In Specific Up Regulation Of Ppar Y Which Blocks Collagen Production. In Phase Ii Clinical Trials For Nash, Aramchol Significantly Reduced Liver Fat, Improved Liver Histology I.E., Ballooning And Fibrosis, Hepatic Biochemistry And Glycemic Parameters With Favorable Safety And Tolerability Profile.Aramchol Is Currently In Phase Iii Registrational Study For Nash And Fibrosis (Armor) And Has Been Granted Fast Track Designation Status By The Fda For The Treatment Of Nash.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!